Contact us

Managed funds

Concentrated Global Growth Fund

The Zurich Investments Concentrated Global Growth Fund is a highly focused international share fund for long-term investors who want to capitalise on the unique opportunities presented by companies with sustainable earnings acceleration. Our strategic investment partner, American Century Investments, manages the fund with the belief that accelerating growth in revenues and earnings results in significant potential for stock price appreciation. The fund offers a concentrated portfolio of the manager’s ‘highest conviction ideas’ in the global market.

 

  • Overview

    How the fund works

    Zurich’s Concentrated Global Growth Fund was launched in Australia in October 2015. American Century is the underlying manager and has been successfully running the strategy for over a decade. The Fund aims to provide investors with long-term capital growth by investing in securities listed on international stock exchanges. The fund aims to outperform the MSCI World (ex-Australia) Accumulation Index in $A (net dividends reinvested) by 3% to 4% over periods of five or more years.

    In this short video, American Century’s Bernard Chua explains the investment philosophy behind Zurich’s Concentrated Global Growth Share Fund.


    Click on the thumbnails below to learn more about the Concentrated Global Growth Fund:
     
     
  • About the manager

    About the manager

    Zurich Investments provides exclusive access to specialist managers recognised as being amongst the best in their area of expertise. We appointed American Century Investments in 2009 to manage the Zurich Investments Global Growth Share Fund, and launched the Zurich Investments Concentrated Global Growth Fund with them in October 2015.

    American Century Investments were established in 1958 and today have over US$155 billion in funds under management and employ 176 investment professionals*.  They have a truly unique ownership structure where over 45% of the company is owned by The Stowers Institute for Medical Research, which allows strong philanthropic support for cancer research.

    The Fund is managed with the belief that accelerating growth in revenues and earnings results in significant potential for stock price appreciation. The focus is on inflection points in company fundamentals with a process designed to uncover stocks that can outperform as earnings growth accelerates, market expectations rise and multiples expand.

     

    Keith Creveling
    Senior Portfolio Manager
    Brent Puff
    Senior Portfolio Manager
    Ted Harlan
    Portfolio Manager
     

    *Date as of 31 December 2017

  • Performance

    Performance


    Performance returns quoted are compound rates of return calculated on exit prices and assume reinvestment of distributions. Returns are calculated net of all ongoing fees and any taxes payable by the fund. The benchmark return shown is a gross return. Figures shown are rounded to two decimal places.

    The full name of the benchmark used in the table is MSCI World (ex-Australia) Accumulation Index in $A (net dividends reinvested).

    *Inception date is 29 October 2015

    Download latest Fund Focus report
  • Charts

    Select Chart:

    Performance figures are net of ongoing fees and expenses. The performance figures quoted are historical, calculated on an annualised basis using daily unit redemption prices, and do not allow for the effects of income tax or inflation. Total returns assume the reinvestment of all distributions. Growth returns are the returns due to change in initial capital value. Distribution returns are the returns due to the distributions paid which may include net realised capital gains. The Net Asset Value is used in the unit price chart.

    The full name of the benchmark used in the chart is MSCI World (ex-Australia) Accumulation Index in $A (net dividends reinvested).

    © Copyright 2018 Morningstar. All rights reserved.

  • Latest insights

    Check here for the latest articles and insights from American Century Investments


    Bernard Chua, Client Portfolio Manager of the Zurich Concentrated Global Growth Fund was in town during March. While he was here, we asked Bernard to share his insights on the key drivers of outperformance in 2017, recent macro developments (including tariffs), the importance of fundamentals and where he is seeing investment opportunities today.

    Click the button below to watch the latest Meet the Manager webcast.

    Brent Puff, Senior Portfolio Manager discusses the outlook for global equity markets in 2018

  • Downloads

    Concentrated Global Growth Fund documents


    Concentrated Global Growth Fund's recent performance

  • The Stowers Story

 

 

For more news and insights from Zurich

   


Recommended by

The Concentrated Global Growth Fund is recommended by these leading research houses:

 

Lonsec
Recommended
The 'Recommended' rating indicates that Lonsec has strong conviction the financial product can generate risk adjusted returns in line with relevant objectives and is considered an appropriate entry point to this asset class or strategy.^

 

Zenith
Recommended
Recommended products are deemed strong investments within their respective asset class, typically rating first quartile on most criteria.#

 

© Zurich

^ The Lonsec Rating (assigned February 2019) presented in this document is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445. The Rating is limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial product(s). Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold Zurich Investment product(s), and you should seek independent financial advice before investing in this product(s). The Rating is subject to change without notice and Lonsec assumes no obligation to update the relevant document(s) following publication. Lonsec receives a fee from the Fund Manager for researching the product(s) using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at: http://www.lonsecresearch.com.au/research-solutions/our-ratings

# The Zenith Investment Partners (“Zenith”) Australian Financial Services License No. 226872 rating (assigned November 2018) referred to in this document is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at http://www.zenithpartners.com.au/RegulatoryGuidelines

Important Information: Before investing in Zurich Investments Concentrated Global Growth Fund please consider the Fund Product Disclosure Statement (PDS)(available through www.zurich.com.au) as the PDS contains important information. Information concerning the Zurich Investments Concentrated Global Growth Fund is general advice only. It does not consider your personal financial circumstances, needs or objectives. You should consider these factors, the appropriateness of the information and the PDS before making a decision. Past performance is not a reliable indicator of future performance. Investments are not available to residents of countries other than Australia. Zurich Investment Management Limited ABN 56 063 278 400, AFSL 232511, GIIN FVHHKJ.00012. ME.036 of 5 Blue Street North Sydney Australia is the Fund responsible entity.